INDICATIONS

PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration ...Read more

Indications Prescribing Information AmgenSupportPlus.com AmgenBiosimilars.com

Bringing Amgen's experience to the retina community

Amgen brings 40+ years of heritage and expertise in development and manufacturing of biologics1

Innovator and Biosimilar Global Snapshot as of 20241-5

35+

FDA-approved

products, including 6+ biosimilar medicines2-4

~100

COUNTRIES

where Amgen products are available1

~10

MILLION

patients are treated 
with an Amgen 
medication each year5

One of the first large-scale independent biotechnology manufacturers, Amgen is known worldwide as a leader in research, development, and manufacturing of complex innovator and biosimilar therapies.1,6

Amgen continues to invest in and grow an already diverse biosimilar portfolio across multiple therapeutic areas

Over one million patients

Over one million patients TREATED
WITH amgen biosimilars GLOBALLY10

Amgen® Biosimilars logo
Our products reflect our commitment to serving patients with serious illness

Amgen Biosimilars are developed, manufactured, and distributed with the same high standards as our innovator biologics1

Amgen has a global network of scientistsSAME GLOBAL NETWORK OF SCIENTISTS
Amgen has the same key manufacturing facilities in North America and EuropeSAME GMP GLOBAL MANUFACTURING FACILITIES
Amgen has a state-of-the-art distribution networkSAME STATE OF THE ART DISTRIBUTION NETWORK
  • Amgen uses the same network of scientists and facilities to manufacture our biosimilar medicines as we do our innovator medicines
  • Both innovator biologics and biosimilars are typically subjected to approximately 250 quality checks during manufacturing2
  • Amgen uses the same distribution infrastructure to promote a consistent supply of both our innovator biologics and biosimilars across the globe

GMP = good manufacturing processes.

Amgen has an incredible track record of reliable supply3,4

We have a proven resilience to deliver for millions of patients, even in the face of challenge, including natural disasters and the pandemic.
At Amgen, we’re committed to every patient, every time

Amgen is a long-standing biotechnology leader committed to developing the biosimilar marketplace

Our biosimilar pipeline is targeted to address the greatest treatment needs without compromising high-level customer service

Amgen’s commitment is to use biosimilars to help support a robust and sustainable healthcare marketplace

Biosimilars can offer a potentially lower cost treatment option for patientsProviding biosimilars as potentially lower cost treatment options for your patients
biosimilar adoptionInvesting in generating 
real-world evidence and helping support successful biosimilar adoption
sustainable marketplaceEncouraging public policies that support long-term sustainability of the marketplace with biosimilars
biosimilar educationInvesting in biosimilar education

SUPPORT FROM AMGEN

WE ARE COMMITTED to providing solution-oriented resources
that can help provide positive biosimilar experiences FOR PATIENTS

Important Safety Information

CONTRAINDICATIONS
  • PAVBLU™ is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in PAVBLU™.
WARNINGS AND PRECAUTIONS
  • Intravitreal injections, including those with aflibercept products, have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion. Proper aseptic injection technique must always be used when administering PAVBLU™. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
  • Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with aflibercept products. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
  • There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including aflibercept products. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
  • The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with aflibercept compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the aflibercept group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with aflibercept compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with aflibercept compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with aflibercept in the first six months of the RVO studies.
ADVERSE REACTIONS
  • Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with aflibercept including endophthalmitis and retinal detachment.
  • The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
  • Patients may experience temporary visual disturbances after an intravitreal injection with PAVBLU™ and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the full Prescribing Information for additional Important Safety Information.

INDICATIONS

PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME) 
  • Diabetic Retinopathy (DR)

Important Safety Information

CONTRAINDICATIONS
  • PAVBLU™ is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in PAVBLU™.